findmyKOL

James Orcutt, MD

Basic profile

Charleston Hematology Oncology Associates

ORCIDNone on fileNPI
RegionCharleston, SC · SoutheastSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

James Orcutt is an Oncology physician affiliated with Charleston Hematology Oncology Associates. OpenAlex indexes 6 publications with 678 citations (h-index 4).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
6publications

Distinct works indexed by OpenAlex.

678citations

Total citations across indexed works.

4h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
65companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

2085 Henry Tecklenburg Dr Fl 2
Charleston, SC 294147710

Telephone

843-577-6957

Provider last certified this registry record 22 Oct 2022.

View the NPPES registry record

Industry payments

65 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    64.7%
    Kinase inhibitor34.3%
    Verzenio60%Calquence40%
    Part D<11 patients
    Aromatase Inhibitor30.4%
    Letrozole100%
    Part D15 patients
  • Blood & clotting

    12.7%
    Factor Xa inhibitor12.7%
    Eliquis100%
    Part D<11 patients
  • Dermatology

    11.8%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor11.8%
    Acyclovir100%
    Part D<11 patients
Where care is delivered (Part B), 202322.7% facility · 77.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”